AlphaStocks
3.3
Weak

BIOMARIN PHARMACEUTICAL INC (BMRN)

Health Care / Biotechnology

S&P MidCap 400

$57.24

Scores poorly across most models. Proceed with caution.

Weak

Score based on 4 of 5 models — moderate confidence

#964out of 1127 in Health Care

Is BIOMARIN PHARMACEUTICAL INC a Good Investment in 2026?

BIOMARIN PHARMACEUTICAL INC (BMRN) scores 3.3 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model is the most favorable, rating BIOMARIN PHARMACEUTICAL INC as Neutral. However, the Graham model rates it Caution — 55% above fair value. BIOMARIN PHARMACEUTICAL INC currently trades above its estimated fair value of $44, suggesting limited upside at current prices. BIOMARIN PHARMACEUTICAL INC ranks #964 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E32.4ROE5.7Market Cap11B

Estimated Fair Value

$43.9130% above

Trading slightly above estimated fair value.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Caution

Business quality & competitive moat

Graham

Caution

55% above fair value

Lynch

Neutral

PEG 2.3 · Fast Grower

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is BIOMARIN PHARMACEUTICAL INC (BMRN) a good investment?
Based on AlphaStocks' composite analysis, BIOMARIN PHARMACEUTICAL INC (BMRN) scores 3.3 out of 10, earning a Weak rating. This score is below average, suggesting caution. Trading slightly above estimated fair value.
What is BIOMARIN PHARMACEUTICAL INC's Piotroski F-Score?
BIOMARIN PHARMACEUTICAL INC's Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is BMRN overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $44, BMRN appears overvalued. The stock currently trades 30% above its estimated fair value. Trading slightly above estimated fair value.
How does BMRN compare to other Health Care stocks?
BIOMARIN PHARMACEUTICAL INC ranks #964 out of 1127 stocks in the Health Care sector, placing it in the top 86% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about BMRN?
AlphaStocks evaluates BMRN using five proven investment models. Piotroski: Neutral; Buffett: Caution; Graham: Caution; Lynch: Neutral. These models are combined into a single composite score of 3.3/10.

Similar Stocks

PARRFTIAZN

Compare BMRN with

BMRN vs PARRBMRN vs FTIBMRN vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer